XELLIA PHARMACEUTICALS ApS: Financial statements 2021
CVR: 61094628
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
XELLIA PHARMACEUTICALS ApS (CVR 61094628) has filed annual accounts for 2021. In 2021, the company reported revenue of DKK 1,792,626,000 and a net result of DKK -503,090,000 compared with DKK -115,666,000 the year before. That is a decrease of 12.2% compared with the year before. The profit margin was -28.1%. Equity in the 2021 report amounted to DKK 2,082,735,000. The solvency ratio was 55.8%. The company had 640 employees in the financial year.
- Revenue
- DKK 1,792,626,000
- Gross Profit
- DKK -46,989,000
- Profit/Loss
- DKK -503,090,000
- Equity
- DKK 2,082,735,000
- Total Assets
- DKK 3,733,699,000
- Employees
- 640
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | 1.8B | -47M | -503.1M | 2.1B | 640 |
| 2020 | 2B | 361.3M | -115.7M | 2.6B | 624 |
| 2019 | 2.3B | 873.5M | 390.7M | 1.4B | 623 |
| 2018 | 1.9B | 576.7M | -74.9M | 1B | 580 |
| 2017 | 1.9B | 528.3M | 91M | 850.8M | 493 |
Official annual report
Find more companies like XELLIA PHARMACEUTICALS ApS
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2021
As of September 13, 2021, Søren Hostrup has joined the board of directors of XELLIA PHARMACEUTICALS ApS.
As of September 13, 2021, Mikkel Lyager Olsen has left the board of directors of XELLIA PHARMACEUTICALS ApS.
XELLIA PHARMACEUTICALS ApS has published its annual report for 2020. Revenue came to DKK 2,042,515,000, and the net result was DKK -115,666,000.
As of April 30, 2021, Lone Thiis has joined the board of directors of XELLIA PHARMACEUTICALS ApS.
As of April 30, 2021, Jakob Christian Andersen has left the board of directors of XELLIA PHARMACEUTICALS ApS.
As of April 29, 2021, Lone Thiis has left the board of directors of XELLIA PHARMACEUTICALS ApS.
About XELLIA PHARMACEUTICALS ApS
XELLIA PHARMACEUTICALS ApS is a Danish company of the type Anpartsselskab based in København S, founded in 1959. The company is registered under the industry Fremstilling af farmaceutiske råvarer. The company was previously named AXELLIA PHARMACEUTICALS ApS and ALPHARMA ApS. The management consists of Michael Kocher. The board consists of Søren Hostrup (chair), Alexander Sebastian Benjamin Sproedt, Hugo Mendes Marques Crespo Dos Reis and Lars Beck Madsen. The company is owned by XELLIA GROUP ApS. The company has 461 employees (2026). In 2025, the company reported revenue of DKK 1,461,516,000 and a net result of DKK 213,738,000 compared with DKK 828,966,000 the year before. Equity in the 2025 report amounted to DKK 404,569,000.
